Turning Discovery Into Health
Genetic and Rare Diseases Information Center (GARD) (nih.gov) scores 68 out of 100 on Brand Analyzer, placing it in the Developing tier among Healthcare brands, Government brands, Non-profit brands, in the 17th percentile of 13210 Healthcare brands.
The Genetic and Rare Diseases Information Center (GARD) is a U.S. government resource that provides patients, families, and the public with accurate, accessible information about rare and genetic diseases. Operated under the National Institutes of Health within the Department of Health and Human Services, GARD offers free assistance through Information Specialists who help connect individuals to disease-specific information, medical experts, and clinical studies. It serves as a trusted, government-backed starting point for navigating the rare disease journey, complementing rather than replacing professional medical advice.
| Brand Name | Genetic and Rare Diseases Information Center (GARD) |
|---|---|
| Domain | nih.gov |
| Industry | Healthcare, Government |
| Founded | 1887 |
| Headquarters | Bethesda |
| Parent Company / Owner | United States Department of Health and Human Services |
| CEO | Lawrence A. Tabak |
| Main Competitors | National Organization for Rare Disorders (NORD) (86/100), Orphanet (76/100), MedlinePlus Genetics (72/100), Genetic Alliance (79/100), Online Mendelian Inheritance in Man (OMIM) (71/100), Global Genes (81/100) |
Moz Domain Authority 95/100 vs category average 41 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Discover how the Genetic and Rare Diseases Information Center Website and Contact Center can help patients and families who have a rare disease." (Meta description: 23 words (ideal length). No OG description (falling back to meta)) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: No structured data or Open Graph tags detected. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Ghost, Angular.
Social footprint: verified profiles on Instagram; no detected presence on X (Twitter), LinkedIn, Facebook, YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked August 2026.
When asked "What is PubMed?", Claude could identify the brand as of August 2026. PubMed is a free search engine developed by the National Library of Medicine (part of NIH) that provides access to millions of citations and abstracts from biomedical and life sciences literature, including MEDLINE. Best known for Being the go-to free database for searching biomedical research papers and abstracts.
When asked "Best brands similar to PubMed?", Claude would recommend Genetic and Rare Diseases Information Center (GARD) as of August 2026. It's the standard reference tool for medical literature searches, so it would naturally come up for anyone looking for trusted healthcare research databases.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Genetic and Rare Diseases Information Center (GARD)'s main competitors in Healthcare: National Organization for Rare Disorders (NORD) (86/100), Orphanet (76/100), MedlinePlus Genetics (72/100), Genetic Alliance (79/100), Online Mendelian Inheritance in Man (OMIM) (71/100).
Sources: Brand Analyzer scan
GARD offers a public website with information on rare and genetic diseases, along with a contact center staffed by Information Specialists. These specialists provide free, personalized assistance to help patients, families, and caregivers find disease-specific information, connect with medical experts, and learn about relevant clinical studies and research opportunities.
Sources: Genetic and Rare Diseases Information Center (GARD) official site
The Genetic and Rare Diseases Information Center (GARD) is a U.S. government medical information resource operated under the National Institutes of Health, part of the Department of Health and Human Services. It provides free, accessible information about rare and genetic diseases to patients, families, and the public. GARD includes both a website and a contact center staffed by Information Specialists who help individuals find disease-specific resources, medical experts, and clinical studies. It is positioned as a trusted, government-backed starting point for those navigating a rare disease diagnosis, though it does not replace professional medical advice.
Sources: Genetic and Rare Diseases Information Center (GARD) official site
Genetic and Rare Diseases Information Center (GARD) has limited AI-search visibility, scoring 33/100 on Brand Analyzer's AI visibility composite (visibility 0, trust 54, recommendation 66). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Genetic and Rare Diseases Information Center (GARD) official site
Yes, GARD is a trustworthy resource because it operates as part of the U.S. Department of Health and Human Services through the National Institutes of Health, a recognized federal medical research agency. Its information is intended to be accurate and accessible, and it explicitly positions itself as a resource that complements, rather than replaces, professional medical advice-encouraging users to consult healthcare providers for diagnosis and treatment decisions.
Sources: Genetic and Rare Diseases Information Center (GARD) official site
Genetic and Rare Diseases Information Center (GARD) was founded in 1887. Genetic and Rare Diseases Information Center (GARD) operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Genetic and Rare Diseases Information Center (GARD) is headquartered in Bethesda. Genetic and Rare Diseases Information Center (GARD) operates in the Healthcare category.
Sources: Wikidata
Genetic and Rare Diseases Information Center (GARD) scores 66/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Genetic and Rare Diseases Information Center (GARD) official site
Genetic and Rare Diseases Information Center (GARD) can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Genetic and Rare Diseases Information Center (GARD) official site
GARD is used by patients diagnosed with rare or genetic diseases, their family members and caregivers, and members of the general public seeking information about such conditions. It also serves as a resource for individuals trying to understand diagnosis options, locate specialists, or find clinical studies related to a specific rare disease.
Sources: Genetic and Rare Diseases Information Center (GARD) official site
Genetic and Rare Diseases Information Center (GARD) scores 33/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Genetic and Rare Diseases Information Center (GARD) has a weak AI-visibility profile at 33/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (66/100) and its weakest is visibility (0/100). It benefits from a Moz Domain Authority of 95/100 and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, no strong Wikidata entry and thin schema.org structured data. In a live check, Claude could already identify Genetic and Rare Diseases Information Center (GARD) from memory (August 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
68 in October 2026, down from 79 in August 2026.
Ranked closest to Genetic and Rare Diseases Information Center (GARD): National Center for Genome Resources (68/100), National Certification Corporation (68/100), National Organization of Nurse Practitioner Faculties (NONPF) (68/100), Non-Profit Software Corporation (68/100).
A step up - brands to learn from: ZT Corporate (71/100), Zorgnet-Icuro (71/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.